Want to see REPL full AI Analyst Report?
REPL Stock Chart & Stats
$9.70
-$0.76(-7.27%)
At close: 4:00 PM EDT
$9.70
-$0.76(-7.27%)
Day’s Range― - ―
52-Week Range$1.50 - $15.71
Previous CloseN/A
Volume3.27M
Average Volume (3M)3.05M
Market Cap
$1.40B
Enterprise Value$988.94
Total Cash (Recent Filing)$195.33M
Total Debt (Recent Filing)$27.86M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Oct 29, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.15
Shares Outstanding94,219,635
10 Day Avg. Volume3,202,601
30 Day Avg. Volume3,049,337
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)4.27
Price to Sales (P/S)0.00
P/FCF Ratio-2.49
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.00Price Target Upside95.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$59.21M
Bulls Say, Bears Say
Bulls Say
Commercial ApprovalAccelerated approval creates Replimune's first pathway to commercialization and an initial revenue stream. Launch and access programs materially change funding dynamics versus purely pre-commercial peers, enabling investment in sales, real-world data collection, and potential revenue that reduces sole reliance on equity raises.
Regulatory ProgressAcceptance of the BLA resubmission and prior favorable advisory committee vote reflect constructive regulatory engagement and lower near-term regulatory uncertainty. A clearer path for RP1 supports longer-term label expansion and commercial strategy, improving the odds of sustained product adoption if confirmatory data follow.
Improved LiquidityThe recent equity raise meaningfully extends runway to support commercialization of TUDRIQEV and ongoing Phase 3 work, reducing immediate fundraising pressure. Better near-term liquidity preserves the ability to invest in manufacturing, launch infrastructure, and key trials, strengthening operational execution capacity.
Bears Say
No Revenue & Heavy BurnAs a clinical-stage biotech with no durable revenue base, Replimune records accelerating operating losses and deeply negative operating cash flow. Persistent cash burn means continued dependence on external financing until product sales scale, making long-term viability sensitive to commercialization success and trial timelines.
Eroding Equity BaseA sharp decline in shareholders' equity has reduced the company's capital cushion and financial resilience. Diminished equity increases the likelihood of further dilution or constrained strategic options if trials or launches underperform, weakening negotiating leverage with partners and creditors over time.
Confirmatory Trial RiskTUDRIQEV's accelerated approval is conditional on positive confirmatory trials. Trial delays or negative results could jeopardize approval status and future sales, creating substantial binary risk to long-term revenue. Reliance on lengthy clinical validation makes sustainable cash flows and profitability uncertain.
Replimune Group News
REPL FAQ
What was Replimune Group’s price range in the past 12 months?
Replimune Group lowest stock price was $1.50 and its highest was $15.71 in the past 12 months.
What is Replimune Group’s market cap?
Replimune Group’s market cap is $1.40B.
When is Replimune Group’s upcoming earnings report date?
Replimune Group’s upcoming earnings report date is Oct 29, 2026 which is in 69 days.
How were Replimune Group’s earnings last quarter?
Replimune Group released its earnings results on Aug 14, 2026. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.694 by -$0.026.
Is Replimune Group overvalued?
According to Wall Street analysts Replimune Group’s price is currently Undervalued.
Does Replimune Group pay dividends?
Replimune Group does not currently pay dividends.
What is Replimune Group’s EPS estimate?
Replimune Group’s EPS estimate is -0.79.
How many shares outstanding does Replimune Group have?
Replimune Group has 94,219,635 shares outstanding.
What happened to Replimune Group’s price movement after its last earnings report?
Replimune Group reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.694. Following the earnings report the stock price went down -1.448%.
Which hedge fund is a major shareholder of Replimune Group?
Currently, no hedge funds are holding shares in REPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Replimune Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (95.88% Upside)
$19.00 (95.88% Upside)
Blogger Sentiment
Neutral
REPL Sentiment 57%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 132.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 27.0%
Last 30 Days ▲ 27.0%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
212.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-46.23%
Trailing 12-Months
Company Description
Replimune Group
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
REPL Stock 12 Month Forecast
Average Price Target
$19.00
▲(95.88% Upside)
Technical Analysis
CytomX Therapeutics
―
Immatics
―
Lyell Immunopharma
―
Candel Therapeutics
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
3.02% Insiders
15.52% Mutual Funds
51.95% Other Institutional Investors
15.76% Public Companies and
Individual Investors